- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00448409
Activity of TroVax® Alone vs. TroVax® Plus GM-CSF in Patients With Prostate Cancer
A Phase II Trial to Assess the Activity of TroVax® Alone vs. TroVax® Plus Granulocyte Macrophage-Colony Stimulating Factor (GM-CSF) in Patients With Progressive Hormone Refractory Prostate Cancer
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Prostate cancer is the second leading cause of cancer death in American men. Hormonal ablation, in the form of medical or surgical castration is the cornerstone of management for metastatic prostate cancer however, treatment options for a patient in whom androgen ablation fails are limited. Second-line hormonal agents are generally associated with low response rates and no documented survival benefit.
Historically, chemotherapy was not considered to have significant activity in hormone refractory prostate cancer (HRPCa). This view has changed within the past 10 years, partly because of the availability of prostate-specific antigen (PSA) measurements to monitor tumor burden. Although it seems that chemotherapy, either as a single agent or combination of agents may lead to clinical responses, reduction in PSA measurements, pain control, or improved quality of life, no benefit in overall survival has been definitively proven. The current standard of care for the treatment of metastatic prostate cancer is hormone therapy (androgen blockade).3,4 When this strategy is no longer effective, few good treatment options are left. For this reason, prostate cancer research has aimed to identify new therapeutic modalities to increase the impact of these parameters as well as prolong patient survival.
A total of 24 men with prostate cancer ranging from non-metastatic rising PSA only disease to bony metastatic disease will be enrolled in the study. All patients will have failed androgen treatment and at least one prior taxane chemotherapy or have refused chemotherapy.
Out of the 24 patients, 12 patients will be treated using TroVax® and 12 will be treated using TroVax® plus GM-CSF.
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
Texas
-
Houston, Texas, United States, 77030
- The Methodist Hospital Research Institute
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Histologically confirmed adenocarcinoma of the prostate.
- Stable or progressive disease after androgen deprivation.
- Karnofsky Performance Status ≥ 60%.
- At least one prior taxane based chemotherapy for prostate cancer therapy (or patient refusal of chemotherapy)
- At least four weeks have lapsed since prior chemotherapy (if administered)
- Patients on stable doses of bisphosphonates that show subsequent tumor progression may continue on this medication; however, patients are not allowed to initiate bisphosphonate therapy within one month prior to starting therapy or throughout the study.
- Major surgery or radiation therapy completed ≥ 4 weeks prior to enrollment.
- Clinically immunocompetent. All patients are assumed to be immunocompetent unless they have been diagnosed as being immunosuppressed, are receiving oral steroids, immunosuppressive chemotherapy for oncology disorders or are receiving immunosuppressive therapy following transplant.
- Free of clinically apparent autoimmune disease (no prior confirmed diagnosis or treatment for autoimmune disease including Systemic Lupus Erythematosis, Grave's disease, Hashimoto's thyroiditis, multiple sclerosis, insulin dependant diabetes mellitus or systemic (non-joint) manifestations of rheumatoid disease).
- Absolute Lymphocyte Count ≥ 500/µl, ANC >1200/µl, Platelet count >100,000/µl, Hemoglobin > 8 mg/dl
- No evidence of active ischemia on ECG
Exclusion Criteria:
- Patients receiving any other hormonal therapy, including any dose of megestrolacetate (Megace), Proscar (finasteride), any herbal product known to decrease PSA levels (e.g., Saw Palmetto and PC-SPES), or any systemic corticosteroid must discontinue the agent for at least 4 weeks prior to enrollment. Progressive disease (as defined above) must be documented after discontinuation of the hormonal therapy.
- Patients that initiate bisphosphonate therapy within one month prior to starting therapy or throughout the study.
- No supplements or complementary medicines/botanicals are permitted during the study
- Major surgery or radiation therapy completed ≤ 4 weeks prior to enrollment.
- Prior radiopharmaceuticals (strontium, samarium) within 8 weeks prior to enrollment.
- "Currently active" second malignancy, other than non-melanoma skin cancer. Patients are not considered to have a "currently active" malignancy if they have completed therapy and are considered by their physician to be at least less than 30% risk of relapse.
- Serious intercurrent infections or nonmalignant medical illnesses that are uncontrolled.
- Psychiatric illnesses/social situations that would limit compliance with protocol requirements.
- Liver function tests (ALT, AST) more than 1.5 x upper limit of normal (ULN). The bilirubin must be within normal limits.
- Renal function creatinine ≥1.5 x ULN.
- Known allergy to egg proteins.
- Known allergy to neomycin.
- History of allergic response to previous vaccinia vaccinations.
- Chronic oral corticosteroid use (especially anti-emetics) unless prescribed as replacement therapy in the case of adrenal insufficiency.
- Known to test positive for HIV or hepatitis B or C.
- Clinical indication of reduced cardiac function or an ejection fraction of ≤ 40%.
- Requirement for radiotherapy (this is a sign of disease progression and is classed as a withdrawal criterion).
- Concurrent chemotherapy, immunotherapy and radiation therapy
- No investigational or commercial agents or therapies other than those included in protocol treatment may be administered with the intent to treat the patient's malignancy.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: 1
TroVax alone
|
11 Intramuscular injection of TroVax® over 45 weeks.
A single dose of 5 x 108 pfu/ml, will be given by an intramuscular injection into the deltoid muscle of the upper arm.
|
Experimental: 2
TroVax plus GM-CSF
|
11 Intramuscular injection of TroVax® over 45 weeks.
A single dose of 5 x 108 pfu/ml, will be given by an intramuscular injection into the deltoid muscle of the upper arm.
168 subcutaneous GM-CSF injections over 45 weeks.
Administered every day as a subcutaneous injection at a dose of 250mcg/m2/d (maximum 500 mcg) in weeks 1 and 2 of each 28 day cycle (total of 14 days per cycle with a total of 12 cycles).
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
PSA response rate to TroVax® and TroVax® in combination with GM-CSF
Time Frame: restaging every 8 weeks
|
restaging every 8 weeks
|
Anti-5T4 antibody levels
Time Frame: 1st 2 cycles every 2 wks; thereafter about every 4 wks
|
1st 2 cycles every 2 wks; thereafter about every 4 wks
|
CD8+ve cellular response to 5T4 antigen as measured by Elispot
Time Frame: at end of study
|
at end of study
|
Assessment of the number of adverse events and serious adverse events in both groups
Time Frame: AEs as occur
|
AEs as occur
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Objective response rate
Time Frame: restaging every 8 weeks
|
restaging every 8 weeks
|
Overall survival of the patients
Time Frame: restaging every 8 weeks
|
restaging every 8 weeks
|
Progression-free survival
Time Frame: restaging every 8 weeks
|
restaging every 8 weeks
|
Time to progression
Time Frame: restaging every 8 weeks
|
restaging every 8 weeks
|
Collaborators and Investigators
Collaborators
Investigators
- Principal Investigator: Robert J Amato, DO, The Methodist Hospital Research Institute
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- HMRI IRB#0106-0009
- TV/PHRPC-001/06 (Other Identifier: Oxford Biomedica)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Prostatic Neoplasms
-
Technische Universität DresdenRecruitingOligometastatic Disease | Prostatic Cancer, Castration-ResistantGermany
-
Australian and New Zealand Urogenital and Prostate...Peter MacCallum Cancer Centre, AustraliaRecruitingCastration Resistant Prostatic CancerAustralia
-
British Columbia Cancer AgencySanofi; Ozmosis Research Inc.UnknownMetastatic Castration-Resistant Prostatic CancerCanada, Australia
-
Janssen Research & Development, LLCCompletedCastration-Resistant Prostatic NeoplasmsCanada, Belgium, United States, Spain, Netherlands, Italy, Russian Federation
-
Universität des SaarlandesRecruitingProstate Cancer Metastatic | Advanced Prostate Carcinoma | Castration Resistant Prostatic CancerGermany
-
Yinghao SunNot yet recruitingCastration-Resistant Prostatic Cancer
-
Institut Claudius RegaudWithdrawnProstatic Cancer, Castration-ResistantFrance
-
University Hospital, GrenobleTerminatedCastration-resistant Prostate CancerFrance
-
Michael Graham PhD, MDUniversity of Iowa; Holden Comprehensive Cancer CenterActive, not recruitingProstate Cancer | Prostatic Neoplasms, Castration-Resistant | Prostatic Neoplasm | Prostatic Cancer Recurrent | Prostatic Cancer MetastaticUnited States
-
Rio de Janeiro State UniversityCompletedProstatic Cancer | Prostatic NeoplasmBrazil
Clinical Trials on TroVax
-
University College, LondonCancer Research UK; Oxford BioMedicaCompletedOvarian Cancer | Fallopian Tube Cancer | Peritoneal CancerUnited Kingdom
-
Cancer Research UKOxford BioMedicaCompletedColorectal Neoplasms
-
Oxford BioMedicaThe Methodist Hospital Research Institute; ORION Clinical ServicesCompletedCarcinoma, Renal CellUnited States
-
Oxford BioMedicaSanofiCompletedClear Cell Renal CarcinomaUnited States, Spain, Israel, United Kingdom, France, Russian Federation, Germany, Poland, Romania, Ukraine
-
Oxford BioMedicaMedSource LLCTerminatedHormone Refractory Prostate CancerUnited States
-
The Methodist Hospital Research InstituteOxford BioMedicaTerminatedProstatic NeoplasmsUnited States
-
Oxford BioMedicaColumbia University; ORION Clinical ServicesCompletedA Study of TroVax Vaccine Given in Conjunction With IL-2 for Treatment of Stage IV Renal Cell CancerCarcinoma, Renal CellUnited States
-
The Methodist Hospital Research InstituteOxford BioMedicaCompletedCarcinoma, Renal CellUnited States
-
OncoMed Pharmaceuticals, Inc.Completed
-
Wales Cancer Trials UnitVelindre NHS Trust; June Hancock Mesothelioma Research Fund; Velindre Cancer...UnknownMesothelioma | Malignant | PleuralUnited Kingdom